Setting a new global standard in brain health innovation, Aker BioMarine’s Lysoveta has been named the Innovation Winner at the 2025 Complementary Medicines Australia (CMA) Industry Awards, recognized for its groundbreaking science and unique delivery technology that enhances brain health through targeted omega-3 transport.
Oslo, Norway, November 27th 2025 – Aker BioMarine is proud to announce that its next-generation brain health ingredient, Lysoveta, has been named the Innovation Winner at the Complementary Medicines Australia (CMA) Annual Conference & 26th Industry Awards in Sydney. This recognition honors the company’s groundbreaking scientific innovation, showcasing its advanced research, technology, and unique delivery format that empower brands to offer best-in-class brain health solutions in Australia and around the world.
A Proud Moment for Aker BioMarine
The CMA Annual Conference in Sydney brought together industry leaders, researchers, and policy experts to explore The Future of Wellness and Longevity, highlighting innovations, consumer trends, scientific breakthroughs, and regulatory landscapes shaping the decades ahead. From advances in preventative health and personalized nutrition to breakthroughs in healthy ageing, the conference showcased how complementary medicines can continue to play a leading role in supporting quality of life, extending healthspans, and meeting the needs of future generations.
"This recognition is a proud milestone for our entire team," said Ross Norris, General Manager, Asia Pacific at Aker BioMarine. "Aker BioMarine greatly values our partnership with the CMA, whose leadership in ensuring consumers have access to safe, high-quality products aligns with our commitment to advocating for the industry, promoting research and innovation, and upholding the highest standards of quality and safety. Being honored with the CMA Innovation Award is a strong validation of our scientific approach and commitment to developing truly innovative solutions across multiple ingredient platforms."
What Makes Lysoveta Stand Out?
Lysoveta is the first and only LPC dietary ingredient proven to cross the blood-brain barrier through the Mfsd2a transporter. By doing so, it delivers essential omega-3 fatty acids DHA and EPA directly to the brain along with critical phospholipids and choline. These nutrients are critical for supporting memory, mood, focus, stress resilience, and overall cognitive performance.
By unlocking this unique and biologically preferred delivery pathway, Lysoveta is not just another supplement, it’s a scientific innovation and game-changer for brain health and long-term wellbeing.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops sustainable marine-based health ingredients. By harnessing the natural, nutritional power of krill and algae, Aker BioMarine has a unique position in its industry by helping address global health challenges, such as omega-3 deficiencies. The ingredient portfolio consists of Superba Krill® Oil, Lysoveta®, Revervia®, and PL+™, and our business model focusses on investing in science to validate the superior delivery of omega-3 benefits possible by krill oil. Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.